Cell Code represents over a decade of groundbreaking research in regenerative therapy, focused on activating and guiding dormant stem cells, known as VSELS, and enhancing platelet activity.

Revolutionary Regenerative Technology

Cell Code’s innovative approach activates dormant VSELS in the blood, which are then reintroduced into the body via an angio-catheter and guided using scalar wave activation technology. In a remarkable 12-person study involving Stage 4 heart failure patients, all participants were successfully removed from the heart transplant list, showcasing the profound potential of this therapy.

The technology’s applications are expansive, addressing areas such as anti-aging, dementia, brain trauma, hair growth, cardiovascular diseases, neurodegenerative conditions, orthopedics, and more.

Version 1 of this breakthrough has already been used in over 500 individuals with extraordinary results. The enhanced Version 2.4 is nearing completion in collaboration with a major U.S. university in Kentucky and institutions in Poland. The RMAT process for FDA fast-track approval is set to begin in March, with plans for technology licensing initiated in early 2023. Cell Code is poised to transform regenerative medicine on a global scale.